Skip to main content

Home/ Nutrition/ Group items tagged lipoxins

Rss Feed Group items tagged

Matti Narkia

Lipoxin - Wikipedia, the free encyclopedia - 0 views

  •  
    Lipoxins are a series of anti-inflammatory mediators. Lipoxins are short lived endogenously produced nonclassic eicosanoids whose appearance in inflammation signals the resolution of inflammation. They are abbreviated as LX, an acronym for lipoxygenase (LO) interaction products. At present two lipoxins have been identified; lipoxin A4 (LXA4) and lipoxin B4 (LXB4)
Matti Narkia

Lipid mediators: lipoxin and aspirin-triggered 15-epi-lipoxins. - Bentham Science Publi... - 0 views

  •  
    Lipid mediators: lipoxin and aspirin-triggered 15-epi-lipoxins. Romano M. Inflamm Allergy Drug Targets. 2006 Apr;5(2):81-90. Review. PMID: 16613567
Matti Narkia

Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 depend... - 0 views

  •  
    Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, Aliberti J. Nat Med. 2006 Mar;12(3):330-4. Epub 2006 Jan 15. PMID: 16415877 doi:10.1038/nm1355\n
Matti Narkia

15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acut... - 0 views

  •  
    15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. J Exp Med. 2004 Jul 5;200(1):69-78. PMID: 15238606
Matti Narkia

Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a rando... - 0 views

  •  
    Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. Epub 2004 Oct 7. PMID: 15471991 doi: 10.1073/pnas.0405445101
Matti Narkia

Lipoxins and resolvins in inflammatory bowel disease. - Inflamm Bowel Dis. 2007 Jun - 0 views

  •  
    Lipoxins and resolvins in inflammatory bowel disease. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Inflamm Bowel Dis. 2007 Jun;13(6):797-9. Review. PMID: 17262807
Matti Narkia

Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. ... - 0 views

  •  
    Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Gangemi S, Pescara L, D'Urbano E, Basile G, Nicita-Mauro V, Davì G, Romano M. Exp Gerontol. 2005 Jul;40(7):612-4. PMID: 15935589 doi:10.1016/j.exger.2005.04.004
Matti Narkia

Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in end... - 0 views

  •  
    Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM. Thromb Haemost. 2007 Jan;97(1):88-98. PMID: 17200775 DOI: 10.1160/TH06-06-0315
Matti Narkia

Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. - ... - 0 views

  •  
    Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Celik GE, Erkekol FO, Misirligil Z, Melli M. Clin Exp Allergy. 2007 Oct;37(10):1494-501. PMID: 17883729 DOI: 10.1111/j.1365-2222.2007.02806.x
Matti Narkia

Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal d... - 0 views

  •  
    Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. Machado FS, Esper L, Dias A, Madan R, Gu Y, Hildeman D, Serhan CN, Karp CL, Aliberti J. J Exp Med. 2008 May 12;205(5):1077-86. Epub 2008 Apr 14. PMID: 18411340 doi:10.1084/jem.20072416
Matti Narkia

Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. - J Immu... - 0 views

  •  
    Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C. J Immunol. 2009 Mar 15;182(6):3819-26. PMID: 19265161 doi:10.4049/jimmunol.0803175
Matti Narkia

Targeting lipoxygenases with care. - ScienceDirect - Chemistry & Biology 2006 Nov - 0 views

  •  
    Targeting lipoxygenases with care. de Souza PM, Newson J, Gilroy DW. Chem Biol. 2006 Nov;13(11):1121-2. PMID: 17113992 doi:10.1016/j.chembiol.2006.11.002  
Matti Narkia

Modulation of inflammation in brain: a matter of fat. - J Neurochem. 2007 May - 0 views

  •  
    Modulation of inflammation in brain: a matter of fat. Farooqui AA, Horrocks LA, Farooqui T. J Neurochem. 2007 May;101(3):577-99. Epub 2007 Jan 25. Review. PMID: 17257165 DOI: 10.1111/j.1471-4159.2006.04371.x
Matti Narkia

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators : Abs... - 0 views

  •  
    Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Serhan CN, Chiang N, Van Dyke TE. Nat Rev Immunol. 2008 May;8(5):349-61. Review. PMID: 18437155 doi:10.1038/nri2294
Matti Narkia

Novel omega -- 3-derived local mediators in anti-inflammation and resolution. - Science... - 0 views

  •  
    Novel omega -- 3-derived local mediators in anti-inflammation and resolution. Serhan CN. Pharmacol Ther. 2005 Jan;105(1):7-21. Review. PMID: 15626453 doi:10.1016/j.pharmthera.2004.09.002
Matti Narkia

RvE1 protects from local inflammation and osteoclast-mediated bone destruction in perio... - 0 views

  •  
    RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. FASEB J. 2006 Feb;20(2):401-3. Epub 2005 Dec 22. PMID: 16373400 doi:10.1096/fj.05-4724fje
Matti Narkia

Fatty acid facts, part III: Cardiovascular disease, or, a fish diet is noy fishy. - [Dr... - 0 views

  •  
    Fatty acid facts, part III: Cardiovascular disease, or, a fish diet is noy fishy. Pauwels EK, Kostkiewicz M. Drug News Perspect. 2008 Dec;21(10):552-61. PMID: 19221636
Matti Narkia

New endogenous anti-inflammatory and proresolving lipid mediators: implications for rhe... - 0 views

  •  
    New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Yacoubian S, Serhan CN. Nat Clin Pract Rheumatol. 2007 Oct;3(10):570-9; quiz 1 p following 589. Review. PMID: 17906612
Matti Narkia

Essential fatty acids and their metabolites could function as endogenous HMG-CoA reduct... - 0 views

  •  
    Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.\nDas UN.\nLipids Health Dis. 2008 Oct 15;7:37. Review.\nPMID: 18922179 \ndoi:10.1186/1476-511X-7-37
1 - 20 of 20
Showing 20 items per page